Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

ABSTRACT

Objective: To describe the response to rituximab in patients with treatment-resistant chronic inflammatory demyelinating polyneuropathy (CIDP) with antibodies against paranodal proteins and correlate the response with autoantibody titers.

Methods: Patients with CIDP and IgG4 anti-contactin-1 (CNTN1) or anti-neurofascin-155 (NF155) antibodies who were resistant to IV immunoglobulin and corticosteroids were treated with rituximab and followed prospectively. Immunocytochemistry was used to detect anti-CNTN1 and anti-NF155 antibodies and ELISA with human recombinant CNTN1 and NF155 proteins was used to determine antibody titers.

Results: Two patients had a marked improvement; another patient improved slightly after 10 years of stable, severe disease; and the fourth patient had an ischemic stroke unrelated to treatment and was lost to follow-up. Autoantibodies decreased in all patients after rituximab treatment.

Conclusions: Rituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/NF155 antibodies who are resistant to conventional therapies.

Classification of evidence: This study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies. Neurology Neuroimmunol Neuroinflamm 2015;2:e149; doi: 10.1212/NXI.0000000000000149

GLOSSARY

CIDP = chronic inflammatory demyelinating polyneuropathy; CNTN1 = contactin-1; IVIg = IV immunoglobulin; MuSK = muscle-specific tyrosine kinase; NF155 = neurofascin-155; ONLS = Overall Neuropathy Limitations Scale; PEx = plasma exchange; PLA2R = M-type phospholipase A2 receptor; R-ODS = Rasch-built Overall Disability Scale.

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a heterogeneous autoimmune neuropathy.1 A subset of patients with CIDP with homogeneous phenotypic features have antibodies against node of Ranvier proteins, such as contactin-1 (CNTN1) and neurofascin-155 (NF155).2-5 CNTN1 is a paranodal protein that is essential to organize the axo-glial junction and preserve node of Ranvier function.6 We previously reported that patients with antibodies against CNTN1 present with an aggressive neuropathy with a predominantly motor phenotype, axonal damage at onset, and, in contrast to most patients with CIDP, a poor response to IV immunoglobulin (IVIg).2 It is important that the anti-CNTN1 antibodies in these patients are of the IgG4 isotype, which preliminary pathologic reports7 and in vitro experiments suggest may be pathogenic.8 NF155 is the glial counterpart of CNTN1 and also plays an essential role in node of Ranvier structure and function.9 We have shown that
anti-NF155 antibodies are associated with a specific CIDP phenotype characterized by predominantly distal motor involvement and prominent intention tremor. The antibodies are also of the IgG4 isotype and these patients also have poor response to IVIg.3

Diseases mediated by antibodies of the IgG4 isotype, such as myasthenia gravis with anti–muscle-specific tyrosine kinase (MusK) antibodies, pemphigus vulgaris, and anti–M-type phospholipase A2 receptor (PLA2R) idiopathic membranous nephropathy, respond well to B cell–depleting therapies. This response appears even in patients resistant to immunosuppressant drugs and is frequently associated with a profound and sustained depletion of autoantibodies.10–12 Considering this, our study aimed to evaluate the response to rituximab in the subset of patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies and to determine whether clinical response is associated with a change in autoantibody titer.

METHODS Patients and samples. We included all patients seen in our clinics and those from other Spanish centers meeting the European Federation of Neurological Societies/Peripheral Nerve Society task force diagnostic criteria13 for CIDP who harbored antibodies against either CNTN1 or NF155 and were resistant to IVIg and corticosteroids. Rituximab was offered to these patients as an off-label treatment following our institution’s protocol for compassionate use of off-label drugs. Patients received 375 mg/m2 once weekly for 4 weeks followed by 1 dose per month for 2 additional doses. Additional rituximab cycles were administered 1 year after treatment in patients not achieving full recovery.

Clinical appointments and blood sampling were scheduled every 3 months during the first year and every 6 months thereafter. Overall Neuropathy Limitations Scale (ONLS)14 and Rasch-built Overall Disability Scale (R-ODS)15 scores were collected prospectively.

Patients that remained significantly disabled (ONLS ≥5) despite treatment with IVIg and corticosteroids were classified as treatment resistant.

Data were recorded in a coded database.

Standard protocol approvals, registrations, and patient consents. Informed consent for study participation was obtained from all patients under a protocol approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau.

Anti-CNTN1 and anti-NF155 antibody detection and titration. Serum antibodies against CNTN1 or NF155 were detected by immunocytochemistry using human CNTN1- or NF155-transfected HEK293 cells, as previously described.2,3 ELISA was used for autoantibody isotype identification and titration, as previously described.3,8 A sample was considered positive when the optical density was higher than that of the average for healthy donors (n = 8) plus 4 SDs. All samples were tested simultaneously. To control for nonspecific IgG titer variation, all samples were also tested with VacCyme ELISA (Binding Site, Barcelona, Spain) for anti–tetanic toxoid antibodies, following the manufacturer instructions. Anti-tetanic antibody levels are presented in IU per ml.

Classification of evidence. The primary objectives of our study were to describe the response to rituximab in patients with treatment-resistant CIDP with antibodies against paranodal proteins and to correlate the response with autoantibody titers. This study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies.

RESULTS We identified 9 patients harboring antibodies against CNTN1 or NF155 meeting inclusion criteria. Four patients were from our clinics (6.5% of all patients with CIDP) and 5 (of 32, 15.6%) were from different Spanish centers in which anti-CNTN1 or NF155 antibodies were suspected because the patients were either IVIg resistant or their clinical features matched patients that were previously described with these antibodies.

Of the 9 patients, 2 died (both anti-CNTN1+, patients 8 and 9), 1 had a complete response to corticosteroids (anti-CNTN1+, patient 7), and 6 were treatment resistant. One of these patients (patient 6, anti-NF155+) was excluded because she had previously received rituximab for a marginal zone B cell lymphoma. Another patient (patient 5, anti-NF155+) declined rituximab treatment. The 4 remaining patients (2 anti-CNTN1+, patients 1 and 4; 2 anti-NF155+, patients 2 and 3) were included in the study and treated with rituximab. The clinical features of these patients have been previously reported.3 Three of the patients improved after rituximab treatment in both R-ODS and ONLS scores. Patients 1 and 2 were both severely disabled and had substantial improvement that persisted at 1 year. Neither had responded to previous therapies except for a transient response to plasma exchange (PExs) that did not last longer than 2 months. Rituximab treatment was scheduled immediately after the last PEx course. Patient 1 improved dramatically after rituximab treatment and was able to be withdrawn from other treatments. He has resumed all previous activities (figure 1A) and has not relapsed to date (16 months after treatment). Patient 2 had substantial improvement with mild residual disability (predominantly distal leg weakness) (figure 1C). Disease duration in these 2 patients was less than 1 year at the initiation of rituximab. Patient 3 improved slightly (figure 1E). This patient had significantly longer disease duration (15 years) than patients 1 and 2 and an EMG showed features consistent with axonal degeneration. This patient did not receive PEx prior to rituximab as he had not responded to a prior PEx course after 3 successful PEx courses at disease onset. Patient 4 was removed from the study because she had a cardioembolic middle cerebral artery infarction soon after...
the first rituximab dose that resulted in severe disability and institutionalization, precluding follow-up evaluations.

Anti-CNTN1 and anti-NF155 antibodies were predominantly of the IgG4 isotype in all 4 patients, as previously described.3,8 Anti-CNTN1 and anti-NF155 antibodies were predominantly of the IgG4 isotype in all 4 patients, as previously described.3,8
IgG4 antibody titers decreased significantly in all patients after rituximab treatment. IgG4 autoantibody titers at 6 months were significantly lower or undetectable by ELISA compared with baseline in the rituximab-treated patients. In contrast, anti-tetanic toxoid autoantibodies remained stable or decreased slightly after rituximab treatment (figure 1, B, D, and F).

To investigate whether the decrease in autoantibody titers was related to treatment or to the normal evolution of a monophasic immune response, we performed the following studies. First, we tested anti-NF155 antibodies in patient 3 from a serum sample extracted 10 years before rituximab treatment. Titers were similar to those at inclusion (figure 1F). Unfortunately, pretreatment autoantibody stability could not be tested in patients 1 and 2 (as in patient 3) because the only prerituximab samples available were the ones shown in figure 1. Second, in patient 5, who declined rituximab treatment, both autoantibody titers and clinical status measured by R-ODS remained stable after 1 year of follow-up despite treatment with corticosteroids and methotrexate (figure 2A). Finally, in the patient (patient 7) who met inclusion criteria but did not receive rituximab due to a complete response to corticosteroids, the clinical response was associated with a highly significant reduction of autoantibody titers after 1 year (figure 2B).

**DISCUSSION** Our study reinforces the diagnostic and therapeutic importance of identifying patients with CIDP harboring IgG4 anti-CNTN1/NF155. These antibodies are biomarkers of a subpopulation of patients with CIDP who are resistant to IVIg and steroids but who can have marked and even dramatic improvement with rituximab.

The high proportion of IVIg-resistant patients with anti-CNTN1 or anti-NF155 antibodies is in contrast to the high IVIg response rates seen in typical CIDP and led us to consider alternative treatments. Rituximab is associated with long-lasting and profound responses in other IgG4-mediated diseases, suggesting that it could be effective in patients with IgG4 anti-CNTN1/NF155 who are resistant to IVIg and corticosteroids. In our cohort, rituximab resulted in a dramatic response in 2 patients and a slight improvement in a third. The fact that disease duration was significantly shorter in the patients who had marked responses suggests that early treatment may be important in order to avoid permanent nerve damage. This hypothesis is supported by the fact that the 2 marked responders had also responded to PEx whereas patient 3, after 3 successful PEx cycles, had become PEx resistant. As response might vary depending on disease duration or axonal damage, early detection of these patients may have prognostic implications.

Some case reports and small case series describe CIDP improvement with rituximab, but there is limited evidence to recommend its systematic use. Despite the small number of patients, our study illustrates how the IgG4 isotype of the antibodies helped in therapy selection based on pathophysiologic homology with other diseases rather than CIDP-specific features. The recent report by Doppler et al. briefly describing 1 IgG4 anti-CNTN1+ patient who also responded to rituximab supports our findings.

Autoantibody titers decreased substantially in all patients after rituximab treatment. IgG4 autoantibody titers at 6 months were significantly lower or undetectable by ELISA compared with baseline in the rituximab-treated patients. In contrast, anti-tetanic toxoid autoantibodies remained stable or decreased slightly after rituximab treatment (figure 2A, B, D, and F).
IgG4-mediated diseases such as pemphigus vulgaris and anti-PLA2R idiopathic membranous nephropathy.10,19
CIDP is a rare disease and patients with IgG4 anti-CNTN1/NF155 CIDP account for less than 10% of all patients with CIDP.2,3,16 Thus the number of patients with CIDP and IgG4 antibodies is very small, which is the main limitation of our study. However, the magnitude and potential relevance of the findings in these few cases suggest that testing for these antibodies can have important therapeutic implications. Clinical and electrophysiologic diagnostic criteria are undoubtedly essential for detecting patients with inflammatory neuropathies so that treatment can be promptly initiated. However, the identification of specific biomarkers should be a research priority in a tissue-specific and heterogeneous disease such as CIDP.20 Infrequent antibodies may define small CIDP subtypes that, in aggregate, represent a relevant proportion of all patients with CIDP. Identifying novel clinical-immunologic associations will refine the diagnosis of CIDP, guide treatment selection, and help monitor response to treatment.

AUTHOR CONTRIBUTIONS
I.I. and L.Q. conceived, designed, and performed the experiments and wrote, edited, and revised the manuscript. L.Q., R.R.-G., E.G., and I.I. analyzed the data. All other authors provided characterized specimens.

ACKNOWLEDGEMENT
The authors thank Fina Araque, Miquel Navas, Dana Assylbekova, and Roser Alba for technical support. The authors thank the patients and their families for their participation.

STUDY FUNDING
This study was funded by the Fondo de Investigaciones Sanitarias—Instituto de Salud Carlos III (13/00014 to I.I. and 13/014 to L.Q.), the European Research Area Network (ACAMIN project), and the GBS-CIDP Foundation. L.Q. is supported by the JR 13/00014 grant of the Fondo de Investigaciones Sanitarias—Instituto de Salud Carlos III.

DISCLOSURE
I. Querol received a travel grant from Bayer-Scheringer and research support from Fondo de Investigaciones Sanitarias, Subprograma Jaul Rodes. R. Rojas-García serves on an advisory board for Pfizer. J. Diaz-Manera received speaker honoraria and a travel grant from Genzyme. A. Ortega-Moreno, M. Jose Sedano, L. Sén-Ballesteros, A. Carvajal, and N. Ortiz report no disclosures. E. Gallardo holds a patent for blood-based assay for dysferlinopathies. I. Illa received a travel grant from Fondo de Investigaciones Sanitarias, Subprograma Jaul Rodes. L. Querol received a travel grant from Bayer-Schering and research support from Fondo de Investigaciones Sanitarias—Instituto de Salud Carlos III.

REFERENCES


Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins
Luis Querol, Ricard Rojas-García, Jordi Díaz-Manera, et al.

*Neurol Neuroimmunol Neuroinflamm* 2015;2;
DOI 10.1212/NXI.0000000000000149

This information is current as of September 3, 2015

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at:</th>
<th><a href="http://nn.neurology.org/content/2/5/e149.full.html">http://nn.neurology.org/content/2/5/e149.full.html</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Supplementary material can be found at:</td>
<td><a href="http://nn.neurology.org/content/suppl/2015/10/31/2.5.e149.DC1">http://nn.neurology.org/content/suppl/2015/10/31/2.5.e149.DC1</a></td>
</tr>
<tr>
<td>References</td>
<td>This article cites 19 articles, 3 of which you can access for free at:</td>
<td><a href="http://nn.neurology.org/content/2/5/e149.full.html##ref-list-1">http://nn.neurology.org/content/2/5/e149.full.html##ref-list-1</a></td>
</tr>
<tr>
<td>Citations</td>
<td>This article has been cited by 8 HighWire-hosted articles:</td>
<td><a href="http://nn.neurology.org/content/2/5/e149.full.html##otherarticles">http://nn.neurology.org/content/2/5/e149.full.html##otherarticles</a></td>
</tr>
<tr>
<td>Subspecialty Collections</td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chronic inflammatory demyelinating polyneuropathy</strong></td>
<td><a href="http://nn.neurology.org//cgi/collection/chronic_inflammatory_demyelinating_polyneuropathy">http://nn.neurology.org//cgi/collection/chronic_inflammatory_demyelinating_polyneuropathy</a></td>
</tr>
<tr>
<td></td>
<td><strong>Class IV</strong></td>
<td><a href="http://nn.neurology.org//cgi/collection/class_iv">http://nn.neurology.org//cgi/collection/class_iv</a></td>
</tr>
<tr>
<td>Permits &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at:</td>
<td><a href="http://nn.neurology.org/misc/about.xhtml#permissions">http://nn.neurology.org/misc/about.xhtml#permissions</a></td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online:</td>
<td><a href="http://nn.neurology.org/misc/addir.xhtml#reprintsus">http://nn.neurology.org/misc/addir.xhtml#reprintsus</a></td>
</tr>
</tbody>
</table>